Gland Pharma reported a steady performance in the September quarter (Q2 FY26), with moderate year-on-year growth across key financial metrics.
The company’s consolidated net profit rose 12.2% to ₹184 crore, compared to ₹164 crore in the same quarter last year. Revenue from operations stood at ₹1,487 crore, marking a 5.8% increase from ₹1,406 crore in Q2 FY25.
EBITDA for the quarter came in at ₹314 crore, up 5.7% from ₹297 crore a year ago. However, the EBITDA margin remained largely unchanged at 21.11%, compared to 21.13% in the previous year, indicating stable operating efficiency.
Gland Pharma shares closed at ₹1,971 on Monday, higher than the opening price of ₹1,942.70. During the session, the stock touched a high of ₹2,034 and a low of ₹1,922.60. The company’s 52-week range stands between ₹1,277.80 and ₹2,131.00.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
